Skip to content

Humanin

This monograph details humanin, a 24-amino acid peptide derived from mitochondria, outlining its discovery, structure, and significant pharmacological properties. It discusses humanin's protective role in cardiovascular and renal health, its mechanisms of action through various signaling pathways, and its potential as a biomarker for diseases such as acute kidney injury and breast cancer. Additionally, ongoing clinical trials investigating its utility in fertility and chronic kidney disease suggest promising implications for personalized medicine.

Intelligence Profile

Clinical Applications

Humanin is a mitochondrial-derived peptide being investigated across multiple clinical conditions, though most evidence comes from preclinical studies with limited human clinical trial data available.

Conditions Under Investigation

Diabetes and Metabolic Disorders
Research suggests humanin may help address diabetes-related complications. In animal models, humanin has been shown to ameliorate testicular damage caused by diabetes and restore metabolic hormone balance, including leptin, ghrelin, irisin, and asprosin levels in diabetic mice. However, human clinical evidence for these applications remains limited.

Retinal and Ocular Conditions
Humanin shows potential for treating retinal degeneration and age-related eye diseases. Studies indicate it may protect retinal pigment epithelium cells from damage and provide neuroprotective effects in models of retinal degeneration, though these findings are primarily from animal research.

Reproductive Health
Emerging research explores humanin's role in protecting reproductive cells. Studies have investigated its protective effects on granulosa cells under oxidative stress conditions and as a potential indicator of semen quality and cryotolerance, though clinical applications in human reproductive medicine are not yet established.

Respiratory Conditions
Preliminary research suggests humanin may have therapeutic potential in acute respiratory distress syndrome (ARDS) through cytoprotective mechanisms, though this remains in early investigational stages.

Current Clinical Trials

Three clinical trials are examining humanin in human patients:

  • A completed observational study investigating humanin levels in cardiac surgery patients
  • Studies examining plasma humanin levels in acute kidney injury and during different anesthesia approaches in kidney transplant patients

Clinical Evidence Limitations

The clinical evidence for humanin remains primarily preclinical, with most research conducted in animal models or cell cultures. While early findings suggest potential therapeutic benefits across multiple conditions, robust human clinical trial data demonstrating safety and efficacy is currently lacking. The transition from promising preclinical results to proven clinical applications requires additional rigorous human studies.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for guidance on specific medical conditions.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.